Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Sep 30, 2024 | (FY)Sep 30, 2023 | (FY)Sep 30, 2022 | (FY)Sep 30, 2021 | |
---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||
Cash from operating activities | -3.88%326.29M | -7.06%339.47M | 15.75%365.25M | 315.54M |
Net profit before non-cash adjustment | 40.47%410.41M | -28.10%292.17M | 156.46%406.39M | --158.46M |
Total adjustment of non-cash items | -25.37%46.97M | 69.61%62.93M | -50.85%37.11M | --75.49M |
-Depreciation and amortization | -6.60%36.98M | 9.75%39.59M | -19.03%36.07M | --44.55M |
-Assets reserve and write-off | ---- | ---- | ---- | --34.81M |
-Other non-cash items | -57.20%9.99M | 2,164.02%23.34M | 126.68%1.03M | ---3.87M |
Changes in working capital | -738.07%-131.09M | 80.01%-15.64M | -195.90%-78.24M | --81.58M |
-Change in receivables | -31.23%-161.26M | 9.89%-122.89M | -12.59%-136.37M | ---121.12M |
-Change in prepaid assets | -11.99%11.95M | -52.08%13.58M | 59.88%28.33M | --17.72M |
-Changes in accounts payable | -362.47%-1M | 168.53%381K | -113.89%-556K | --4M |
-Provision for loans, leases and other losses | 28.54%125.89M | 7.72%97.94M | 65.27%90.92M | --55.01M |
-Changes in other current assets | -28.74%-319.77M | -3.59%-248.39M | -46.68%-239.78M | ---163.47M |
-Changes in other current liabilities | -12.57%213.11M | 36.01%243.75M | -38.08%179.22M | --289.44M |
Dividends paid (cash flow from operating activities) | ||||
Dividends received (cash flow from operating activities) | ||||
Interest paid (cash flow from operating activities) | -33.57%-1.52M | -8.90%-1.14M | -18.89%-1.05M | -879K |
Interest received (cash flow from operating activities) | -81.52%524K | 17.34%2.84M | 99.09%2.42M | 1.21M |
Tax refund paid | 53.56%-128.66M | -213.00%-277.06M | 32.85%-88.52M | -131.81M |
Other operating cash inflow (outflow) | 0 | -1K | 0 | 6.19M |
Operating cash flow | 206.73%196.63M | -76.95%64.11M | 46.18%278.11M | --190.25M |
Investing cash flow | ||||
Net PPE purchase and sale | 67.19%-3.22M | -188.15%-9.82M | 85.74%-3.41M | ---23.9M |
Net intangibles purchase and sale | -118.87%-48.24M | -18.71%-22.04M | 19.30%-18.57M | ---23.01M |
Net changes in other investments | 63.24%-7.95M | -315.97%-21.62M | 49.09%-5.2M | ---10.21M |
Investing cash flow | -11.08%-59.41M | -96.82%-53.48M | 52.43%-27.17M | ---57.12M |
Financing cash flow | ||||
Net issuance payments of debt | -96.95%3.14M | 143.02%102.89M | -57.14%42.34M | --98.77M |
Net common stock issuance | --595.13M | --0 | ---- | ---- |
Increase or decrease of lease financing | -8.69%-4.77M | -50.00%-4.39M | ---2.92M | ---- |
Net other fund-raising expenses | 0.00%-1K | 0.00%-1K | ---1K | ---- |
Financing cash flow | 502.54%593.5M | 149.93%98.5M | -60.10%39.41M | --98.77M |
Net cash flow | ||||
Beginning cash position | 6.73%1.73B | 21.83%1.62B | 21.11%1.33B | --1.1B |
Current changes in cash | 569.62%730.72M | -62.42%109.13M | 25.20%290.35M | --231.91M |
Cash adjustments other than cash changes | 0.00%1K | --1K | ---- | ---- |
End cash Position | 42.25%2.46B | 6.73%1.73B | 21.83%1.62B | --1.33B |
Free cash flow | 350.23%145.17M | -87.41%32.24M | 78.68%256.13M | --143.34M |
Currency Unit | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |